Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 9

Examining the Evolving 3L Treatment Landscape for mCRC

, , , ,

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Molecular Testing and Barriers in mCRC
    EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC
    EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
    EP. 4: Exploring Toxicities for Second Line Treatments in mCRC
    EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
    EP. 6: Factors Driving 3L Therapeutic Selection for mCRC
    EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial
    EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
    Now Viewing
    EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC
    EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR
    EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer
    1. Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
    2. Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
      1. Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
      2. Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (Bekaii-Saab T, et al. ASCO 2024. Abstract 3579.)
        1. Impact of prior bevacizumab
      3. Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing:
        1. Impact of prior fluoropyrimidine (Fakih, et al. ASCO GI 2024. Abstract 114)
        2. Impact of prior bevacizumab
      4. Dr Cohen: Regorafenib and/or TAS-102 sequencing (Signorelli C, et al. ASCO 2024. Abstract e15553)

    x